Altimmune, Inc. (ALT) financial statements (2021 and earlier)

Company profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments216373492211619
Cash and cash equivalents11693491541619
Short-term investments10028  67  
Restricted cash and investments0014   
Receivables122410  0
Other undisclosed current assets2011120
Total current assets:2303939232221719
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment1111000
Intangible assets, net (including goodwill)13131439222
Goodwill    222
Intangible assets, net (excluding goodwill)13131439   
Other noncurrent assets0000 00
Total noncurrent assets:15151540233
TOTAL ASSETS:2455455632252022
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1244420110
Accounts payable1000110
Accrued liabilities1144400 
Taxes payable    3  
Interest and dividends payable    197  
Debt  00  1
Derivative instruments and hedges, liabilities    100
Restructuring reserve    00 
Deferred revenue and credits0   
Other liabilities    00 
Other undisclosed current liabilities    211
Total current liabilities:1245420523
Noncurrent Liabilities
Long-term debt and lease obligation2225   
Long-term debt, excluding current maturities2225   
Liabilities, other than long-term debt5306012
Accounts payable and accrued liabilities      1
Deferred tax liabilities, net06   
Restructuring reserve     0 
Other liabilities    000
Business combination, contingent consideration, liability53     
Derivative instruments and hedges, liabilities     01
Other undisclosed noncurrent liabilities      (1)
Total noncurrent liabilities:75211011
Total liabilities:19961420534
Stockholders' equity
Stockholders' equity attributable to parent226464839191718
Common stock0000000
Additional paid in capital41718817012249240239
Accumulated other comprehensive loss(5)(5)(5)(5)(0) (0)
Accumulated deficit(186)(137)(117)(78)(30)(224)(220)
Other undisclosed stockholders' equity   9   
Total stockholders' equity:226464849191718
TOTAL LIABILITIES AND EQUITY:2455455632252022

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues86101151110
Revenue, net1151110
Cost of revenue
(Cost of Goods and Services Sold)
     (0)(0)
Gross profit:86101151010
Operating expenses(63)(27)(53)(63)(16)(14)(20)
Other undisclosed operating income     00
Operating loss:(55)(21)(43)(52)(11)(3)(10)
Nonoperating income (expense)01(2)(0)21600
Investment income, nonoperating0100   
Other nonoperating income (expense)000000(0)
Interest and debt expense(0)(0)(0)(0) (0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes     00
Income (loss) from continuing operations before equity method investments, income taxes:(54)(21)(46)(52)205(3)(10)
Other undisclosed income from continuing operations before income taxes0000   
Income (loss) from continuing operations before income taxes:(54)(21)(45)(52)205(3)(10)
Income tax expense (benefit)5066(11)(0)(0)
Net income (loss) attributable to parent:(49)(21)(39)(46)194(3)(10)
Preferred stock dividends and other adjustments (0)(3)(5)   
Net income (loss) available to common stockholders, diluted:(49)(21)(42)(51)194(3)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(49)(21)(39)(46)194(3)(10)
Other comprehensive income (loss)   3  (10)
Other undisclosed comprehensive income (loss)(0)0     
Comprehensive income (loss):(49)(21)(39)(43)194(3)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (0) (0)0 
Comprehensive income (loss), net of tax, attributable to parent:(49)(21)(40)(43)194(3)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: